The World Health Organization has approved a Covid vaccine made by US pharma giant Novavax for emergency use.
Tuesday's announcement comes a day after the European Medicines Agency, the EU medicines regulator,gave the green light to Nuvaxovid.
WHO said Nuvaxovid was around 90-percent effective at reducing symptomatic cases of Covid-19 in two major clinical studies, one in Britain and the other in the United States and Mexico, involving more than 45,000 people.
In a separate document, WHO's Strategic Advisory Group of Experts on Immunisation recommended the new vaccine for use in people over the age of 18, with an interval of three to four weeks between the two doses.
"The vaccine should not be administered with an interval of less than three weeks," it warned.
It can be kept at refrigerated temperatures between 2 and 8 degrees Celsius, giving it a logistical advantage in difficult-to-access regions over the mRNA vaccines, which must be stored at ultra-low temperatures.
READ MORE:Omicron replaces Delta to become dominant Covid version in US
Among the Covid vaccines already handed a WHO EUL is the Covovax shot, a version of Novavax's vaccine made by the Serum Institute of India under license from the US-based company.
It was authorised on December 17.
Also figuring on the list are the mRNA vaccines produced by BioNTech/Pfizer and Moderna, Johnson&Johnson, AstraZeneca (which is counted twice for the versions made in Europe and in India), the Indian-made Covaxin and Chinese-made Sinopharm and Sinovac.
Tried and tested approach
The WHO also recently resumed evaluating the Russian-made Sputnik V vaccine against Covid-19, after several months in limbo, as it waited for additional data.
Nuvaxovid is made from a more conventional technology than others already approved, which has led officials in Brussels to express hope that this will help persuade those hesitant about vaccination to come forward.
The jab uses a traditional technology involving proteins found on coronavirus spike proteins that trigger an immune response.
It is a tried and tested approach, used for decades to vaccinate people against diseases including hepatitis B and whooping cough.
A so-called emergency use listing (EUL) by the WHO paves the way for countries worldwide to quickly approve and import a vaccine for distribution.
It also opens the door for them to enter the Covax global vaccine-sharing scheme, set up to provide equitable access to doses around the world and particularly in poorer countries.
The two-shot Nuvaxovid jab is the 10th Covid vaccine issued an EUL by the UN health agency.
READ MORE:Europe divided over kids' Covid vaccines
